Celltrion
068270 · KRX · Healthcare · Biopharmaceuticals
About the company
Celltrion is a South Korean biopharmaceutical company focused on the development and commercialization of biosimilar medicines, including biosimilars of major biologics such as infliximab and trastuzumab. The company operates one of Asia's largest mammalian cell culture biomanufacturing facilities in Incheon. Celltrion markets its products globally through its own distribution network and strategic partnerships.
| Exchange | KRX |
| Ticker | 068270 |
| Sector | Healthcare · Biopharmaceuticals |
| Indicative market cap USD | $24.00B |
| Website | Visit website |
Live quote
Loading live price…
| Market cap | |
| Day range | |
| 52-week range |
Where to buy
On its home market (KRX), it is accessible through global brokers that offer that exchange:
- Interactive Brokers — Direct access to 90+ markets worldwide, including many emerging exchanges.
- Saxo Bank — Multi-market access across Asia, Europe and the Middle East.
- Charles Schwab (Global) — Foreign ordinary shares on select markets; US-listed ADRs and ETFs.
- Fidelity International Trading — International stock trading on a number of developed and emerging markets.
- Korea Exchange, operating the KOSPI Market for large-cap equities, the KOSDAQ Market for technology and growth companies, and the KONEX Market for small and medium-sized enterprises. — official exchange listing
Availability information only. Not a recommendation or an offer to buy. Confirm eligibility, fees and current availability with your broker.
Other companies in South Korea
Company data and any live price are indicative, may be delayed or inaccurate, and are for research only. Not investment advice. Verify with the exchange, the company's filings and your broker.